CPSE:GMABBiotechs
Assessing Genmab (CPSE:GMAB) Valuation As New ASCO And EHA Pipeline Data Nears
Genmab (CPSE:GMAB) is drawing fresh attention after announcing 23 abstracts for the 2026 ASCO and EHA meetings, largely centered on epcoritamab and other late stage oncology candidates in ongoing clinical trials.
See our latest analysis for Genmab.
Genmab's latest ASCO and EHA abstracts come after a mixed price pattern, with the share price up 3.62% over the past week but down 14.45% year to date. The 1 year total shareholder return of 23.17% contrasts with weaker 3 and 5 year total...